A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

CONCLUSION: A one-month mid-treatment break and reassessment may reduce the odds of treatment related toxicity without compromising LC. PMID: 31431377 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31431377?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - August 16, 2019 Category: Radiology Authors: Jackson WC, Suresh K, Maurino C, Feng M, Cuneo KC, Ten Haken RK, Lawrence TS, Schipper MJ, Owen D Tags: Radiother Oncol Source Type: research